Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Valerius

Showing results (51-60 of 106) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2011
Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagyJantine E Bakema, Sonja H Ganzevles, Donna M Fluitsma, et al.
Frontiers in Immunology|March 4, 2026
Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case reportTorsten Schroeder, Guranda Chitadze, Justina Dargvainiene, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutationsMatthias Peipp, Tanja Schneider-Merck, Michael Dechant, et al.
Cancer Science|July 2, 2011
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)Katja Klausz, Sven Berger, Jeroen J Lammerts van Bueren, et al.
Blood|July 13, 2017
An Fc-engineered CD19 antibody eradicates MRD in patient-derived <i>MLL</i>-rearranged acute lymphoblastic leukemia xenograftsDenis M Schewe, Ameera Alsadeq, Cornelia Sattler, et al.
Antibodies (Basel, Switzerland)|November 20, 2020
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-EngineeringSophia Roßkopf, Klara Marie Eichholz, Dorothee Winterberg, et al.
Frontiers in Immunology|September 2, 2022
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumabNiklas Baumann, Christian Arndt, Judith Petersen, et al.
The Journal of Biological Chemistry|April 11, 2021
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and METJoost Neijssen, Rosa M F Cardoso, Kristen M Chevalier, et al.
Mabs|October 16, 2015
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingSaskia Meyer, Maaike Nederend, J H Marco Jansen, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Pageof 11

Showing results (51-60 of 106) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|June 10, 2011
Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagyJantine E Bakema, Sonja H Ganzevles, Donna M Fluitsma, et al.
Frontiers in Immunology|March 4, 2026
Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case reportTorsten Schroeder, Guranda Chitadze, Justina Dargvainiene, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutationsMatthias Peipp, Tanja Schneider-Merck, Michael Dechant, et al.
Cancer Science|July 2, 2011
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)Katja Klausz, Sven Berger, Jeroen J Lammerts van Bueren, et al.
Blood|July 13, 2017
An Fc-engineered CD19 antibody eradicates MRD in patient-derived <i>MLL</i>-rearranged acute lymphoblastic leukemia xenograftsDenis M Schewe, Ameera Alsadeq, Cornelia Sattler, et al.
Antibodies (Basel, Switzerland)|November 20, 2020
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-EngineeringSophia Roßkopf, Klara Marie Eichholz, Dorothee Winterberg, et al.
Frontiers in Immunology|September 2, 2022
Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumabNiklas Baumann, Christian Arndt, Judith Petersen, et al.
The Journal of Biological Chemistry|April 11, 2021
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and METJoost Neijssen, Rosa M F Cardoso, Kristen M Chevalier, et al.
Mabs|October 16, 2015
Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targetingSaskia Meyer, Maaike Nederend, J H Marco Jansen, et al.
Oncoimmunology|March 5, 2016
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30Christian Kellner, Andreas Günther, Andreas Humpe, et al.
Pageof 11